Cargando…

Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study

Although several studies have shown promising clinical outcomes of phage therapy in patients with orthopedic device-related infections, questions remain regarding the optimal application protocol, systemic effects, and the impact of the immune response. This study provides a proof-of-concept of phag...

Descripción completa

Detalles Bibliográficos
Autores principales: Onsea, Jolien, Post, Virginia, Buchholz, Tim, Schwegler, Hella, Zeiter, Stephan, Wagemans, Jeroen, Pirnay, Jean-Paul, Merabishvili, Maya, D’Este, Matteo, Rotman, Stijn G., Trampuz, Andrej, Verhofstad, Michael H. J., Obremskey, William T., Lavigne, Rob, Richards, R. Geoff, Moriarty, T. Fintan, Metsemakers, Willem-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672900/
https://www.ncbi.nlm.nih.gov/pubmed/34908439
http://dx.doi.org/10.1128/spectrum.01736-21
_version_ 1784615436012224512
author Onsea, Jolien
Post, Virginia
Buchholz, Tim
Schwegler, Hella
Zeiter, Stephan
Wagemans, Jeroen
Pirnay, Jean-Paul
Merabishvili, Maya
D’Este, Matteo
Rotman, Stijn G.
Trampuz, Andrej
Verhofstad, Michael H. J.
Obremskey, William T.
Lavigne, Rob
Richards, R. Geoff
Moriarty, T. Fintan
Metsemakers, Willem-Jan
author_facet Onsea, Jolien
Post, Virginia
Buchholz, Tim
Schwegler, Hella
Zeiter, Stephan
Wagemans, Jeroen
Pirnay, Jean-Paul
Merabishvili, Maya
D’Este, Matteo
Rotman, Stijn G.
Trampuz, Andrej
Verhofstad, Michael H. J.
Obremskey, William T.
Lavigne, Rob
Richards, R. Geoff
Moriarty, T. Fintan
Metsemakers, Willem-Jan
author_sort Onsea, Jolien
collection PubMed
description Although several studies have shown promising clinical outcomes of phage therapy in patients with orthopedic device-related infections, questions remain regarding the optimal application protocol, systemic effects, and the impact of the immune response. This study provides a proof-of-concept of phage therapy in a clinically relevant rabbit model of fracture-related infection (FRI) caused by Staphylococcus aureus. In a prevention setting, phage in saline (without any biomaterial-based carrier) was highly effective in the prevention of FRI, compared to systemic antibiotic prophylaxis alone. In the subsequent study involving treatment of established infection, daily administration of phage in saline through a subcutaneous access tube was compared to a single intraoperative application of a phage-loaded hydrogel and a control group receiving antibiotics only. In this setting, although a possible trend of bacterial load reduction on the implant was observed with the phage-loaded hydrogel, no superior effect of phage therapy was found compared to antibiotic treatment alone. The application of phage in saline through a subcutaneous access tube was, however, complicated by superinfection and the development of neutralizing antibodies. The latter was not found in the animals that received the phage-loaded hydrogel, which may indicate that encapsulation of phages into a carrier such as a hydrogel limits their exposure to the adaptive immune system. These studies show phage therapy can be useful in targeting orthopedic device-related infection, however, further research and improvements of these application methods are required for this complex clinical setting. IMPORTANCE Because of the growing spread of antimicrobial resistance, the use of alternative prevention and treatment strategies is gaining interest. Although the therapeutic potential of bacteriophages has been demonstrated in a number of case reports and series over the past decade, many unanswered questions remain regarding the optimal application protocol. Furthermore, a major concern during phage therapy is the induction of phage neutralizing antibodies. This study aimed at providing a proof-of-concept of phage therapy in a clinically relevant rabbit model of fracture-related infection caused by Staphylococcus aureus. Phage therapy was applied as prophylaxis in a first phase, and as treatment of an established infection in a second phase. The development of phage neutralizing antibodies was evaluated in the treatment study. This study demonstrates that phage therapy can be useful in targeting orthopedic device-related infection, especially as prophylaxis; however, further research and improvements of these application methods are required.
format Online
Article
Text
id pubmed-8672900
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-86729002021-12-16 Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study Onsea, Jolien Post, Virginia Buchholz, Tim Schwegler, Hella Zeiter, Stephan Wagemans, Jeroen Pirnay, Jean-Paul Merabishvili, Maya D’Este, Matteo Rotman, Stijn G. Trampuz, Andrej Verhofstad, Michael H. J. Obremskey, William T. Lavigne, Rob Richards, R. Geoff Moriarty, T. Fintan Metsemakers, Willem-Jan Microbiol Spectr Research Article Although several studies have shown promising clinical outcomes of phage therapy in patients with orthopedic device-related infections, questions remain regarding the optimal application protocol, systemic effects, and the impact of the immune response. This study provides a proof-of-concept of phage therapy in a clinically relevant rabbit model of fracture-related infection (FRI) caused by Staphylococcus aureus. In a prevention setting, phage in saline (without any biomaterial-based carrier) was highly effective in the prevention of FRI, compared to systemic antibiotic prophylaxis alone. In the subsequent study involving treatment of established infection, daily administration of phage in saline through a subcutaneous access tube was compared to a single intraoperative application of a phage-loaded hydrogel and a control group receiving antibiotics only. In this setting, although a possible trend of bacterial load reduction on the implant was observed with the phage-loaded hydrogel, no superior effect of phage therapy was found compared to antibiotic treatment alone. The application of phage in saline through a subcutaneous access tube was, however, complicated by superinfection and the development of neutralizing antibodies. The latter was not found in the animals that received the phage-loaded hydrogel, which may indicate that encapsulation of phages into a carrier such as a hydrogel limits their exposure to the adaptive immune system. These studies show phage therapy can be useful in targeting orthopedic device-related infection, however, further research and improvements of these application methods are required for this complex clinical setting. IMPORTANCE Because of the growing spread of antimicrobial resistance, the use of alternative prevention and treatment strategies is gaining interest. Although the therapeutic potential of bacteriophages has been demonstrated in a number of case reports and series over the past decade, many unanswered questions remain regarding the optimal application protocol. Furthermore, a major concern during phage therapy is the induction of phage neutralizing antibodies. This study aimed at providing a proof-of-concept of phage therapy in a clinically relevant rabbit model of fracture-related infection caused by Staphylococcus aureus. Phage therapy was applied as prophylaxis in a first phase, and as treatment of an established infection in a second phase. The development of phage neutralizing antibodies was evaluated in the treatment study. This study demonstrates that phage therapy can be useful in targeting orthopedic device-related infection, especially as prophylaxis; however, further research and improvements of these application methods are required. American Society for Microbiology 2021-12-15 /pmc/articles/PMC8672900/ /pubmed/34908439 http://dx.doi.org/10.1128/spectrum.01736-21 Text en Copyright © 2021 Onsea et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Onsea, Jolien
Post, Virginia
Buchholz, Tim
Schwegler, Hella
Zeiter, Stephan
Wagemans, Jeroen
Pirnay, Jean-Paul
Merabishvili, Maya
D’Este, Matteo
Rotman, Stijn G.
Trampuz, Andrej
Verhofstad, Michael H. J.
Obremskey, William T.
Lavigne, Rob
Richards, R. Geoff
Moriarty, T. Fintan
Metsemakers, Willem-Jan
Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
title Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
title_full Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
title_fullStr Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
title_full_unstemmed Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
title_short Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study
title_sort bacteriophage therapy for the prevention and treatment of fracture-related infection caused by staphylococcus aureus: a preclinical study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672900/
https://www.ncbi.nlm.nih.gov/pubmed/34908439
http://dx.doi.org/10.1128/spectrum.01736-21
work_keys_str_mv AT onseajolien bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT postvirginia bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT buchholztim bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT schweglerhella bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT zeiterstephan bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT wagemansjeroen bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT pirnayjeanpaul bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT merabishvilimaya bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT destematteo bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT rotmanstijng bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT trampuzandrej bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT verhofstadmichaelhj bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT obremskeywilliamt bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT lavignerob bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT richardsrgeoff bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT moriartytfintan bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy
AT metsemakerswillemjan bacteriophagetherapyforthepreventionandtreatmentoffracturerelatedinfectioncausedbystaphylococcusaureusapreclinicalstudy